Long-Term Effects of Dulaglutide on People with T2D: Results from the REWIND Trial
As we know, people with diabetes have twice the risk of developing cardiovascular disease and as a result, have twice the rate of cardiovascular events such as heart attacks and strokes. Research also indicates that people with type 2 diabetes (T2D) also have a higher risk of developing kidney disease. The REWIND Trial was the longest study ever to assess effects of a GLP-1 drug on cardiovascular events in diabetes and Beyond Type 2 has the breakdown:
Study: The REWIND Trial (Researching CV Events with a Weekly Incretin in Diabetes)
Goal: To assess the long-term effect of dulaglutide, a GLP-1 receptor agonist, on cardiovascular events. This study was conducted in a lower risk group with type 2 diabetes. Currently, there are five published randomized control trials lasting up to 3.8 years to determine the effects of the GLP-1 receptor agonists in people with T2D who’ve had a cardiovascular event or have an increased risk of cardiovascular disease.
Methods: This study was conducted in a group of 9,901 participants with type 2.
Results: The researchers behind the REWIND trial presented their data on the effects of five years of treatment with dulaglutide compared to placebo on cardiovascular outcomes. The results found that dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with type 2 diabetes.
“This trial shows that dulaglutide can safely reduce these events while improving diabetes control and modestly lowering weight and blood pressure in middle-aged people with type 2 diabetes,” according to Hertzel C. Gerstein, principal investigator for the study, professor of medicine at McMaster and deputy director of the PHRI.
This article is part of Beyond Type 2’s ADA 2019 coverage. For full ADA 2019 coverage, click here.